2017•BMJRequires access
NICE recommends ixekizumab for persistent severe plaque psoriasis
Susan Mayor
Open publisher page 0 citations
Abstract
The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.
The guidance recommended ixekizumab as an option for treating plaque psoriasis in adults, but only if they had severe disease (a …